Work

The GLP-1 analog, exendin-4, improves bone material properties and strength through a central relay in ovariectomized mice

Year: 2025

Type: article

Abstract: This study discovered that medications mimicking GLP-1, like exendin-4, improve bone strength and structure in mice, including better bone volume and collagen quality. Interestingly, exendin-4's effects were observed when delivered to the brain but not when prevented from reaching it. This suggests GLP-1 influences bones through brain signals rather than acting directly on bone. Although GLP-1 treatments show promise for preventing bone weakness, more research is needed to understand this brain-bone connection.

Source: American Journal of Physiology-Endocrinology and Metabolism

DOI: 10.1152/ajpendo.00086.2025

Authors: Morgane Mermet, Jessica Denom, Aleksandra Mieczkowska, Méline Wery, Emma Biggs, Fiona M. Gribble, Frank Reimann, Christophe Magnan, Céline Cruciani-Guglielmacci, Guillaume Mabilleau

Institutions: Inserm, Oniris, Université d'Angers, Nantes Université, Centre National de la Recherche Scientifique, Université Paris Cité, Unit of Functional and Adaptive Biology, University of Cambridge, Wellcome/MRC Institute of Metabolic Science, MRC Metabolic Diseases Unit, Centre Hospitalier Universitaire d'Angers

Language: English

Topic: Bone health and osteoporosis research

Subfield: Orthopedics and Sports Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funders: Canadian Institute for Theoretical Astrophysics, Wellcome Trust, UK Research and Innovation, Institut National de la Santé et de la Recherche Médicale, Universite Angers, Medical Research Council, Société Française de Rhumatologie

Awards: G1045075726, Targeting the gut in metabolic disease, G271718852, G3850766221, G8128783587, Targeting the gut in metabolic disease, G905023109

OpenAlex ID: W4413106790

FWCI: 2.831

Cites: 56

Cited by: 3

Related to: 10